Compare · MASS vs TMO
MASS vs TMO
Side-by-side comparison of 908 Devices Inc. (MASS) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MASS and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $174.30B, about 683.5x MASS ($255.0M).
- Over the past year, MASS is up 21.4% and TMO is up 10.7% - MASS leads by 10.6 points.
- MASS has been more active in the news (11 items in the past 4 weeks vs 10 for TMO).
- TMO has more recent analyst coverage (25 ratings vs 5 for MASS).
- Company
- 908 Devices Inc.
- Thermo Fisher Scientific Inc
- Price
- $6.81-0.15%
- $469.06-2.15%
- Market cap
- $255.0M
- $174.30B
- 1M return
- +9.66%
- -5.16%
- 1Y return
- +21.39%
- +10.74%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 11
- 10
- Recent ratings
- 5
- 25
908 Devices Inc.
908 Devices Inc. develops and sells measurement devices for chemical and biochemical analysis in North America, Europe, the Middle East, Africa, and the Asia Pacific. It offers handheld and desktop mass spectrometry (Mass Spec) devices for the point-of-need applications in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. Its products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest MASS
- 908 Devices to Report First Quarter 2026 Financial Results on May 6, 2026
- SEC Form 4 filed by SVP, Sales & Product Marketing Kenneweg John
- SEC Form DEFA14A filed by 908 Devices Inc.
- SEC Form DEF 14A filed by 908 Devices Inc.
- SEC Form 4 filed by Otitoju Kolawole A.
- SEC Form 3 filed by new insider Otitoju Kolawole A.
- 908 Devices Appoints Kola Otitoju as Chief Business & Strategy Officer and Announces an Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 4 filed by Mccallion Kevin J.
- SEC Form 4 filed by Mccallion Kevin J.
- SEC Form 4 filed by Brown Christopher D.
Latest TMO
- SEC Form 10-Q filed by Thermo Fisher Scientific Inc
- President & COO Pettiti Gianluca sold $185,064 worth of shares (400 units at $462.66) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 25,051 units (SEC Form 4)
- Thermo Fisher Scientific to Host Investor Day
- Thermo Fisher Scientific Signs Agreement to Sell its Microbiology Business to Astorg
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Thermo Fisher Scientific Reports First Quarter 2026 Results
- AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost Advantages
- Thermo Fisher Scientific Expands Global Biobank Leadership Through Strategic Collaboration with PRECISE-SG100K Singapore to Advance Population-Scale Proteomics
- SEC Form DEFA14A filed by Thermo Fisher Scientific Inc
- SEC Form DEF 14A filed by Thermo Fisher Scientific Inc